

Table S1. Patients' characteristics and cutaneous adverse reactions (CAR) of 26 patients with adult T-cell leukaemia-lymphoma (ATL) treated by mogamulizumab

Case	Age, years/sex	Treatment cycles of mogamulizumab	ATL subtype	Previous treatment regimens, n	At the start of mogamulizumab treatment			Best response				Cause of death					
					LDH (IU/l)	sIL-2R (U/ml)	ATL lesions	Infusion reaction	CAR Grade	General	PB		LN	Skin	PFS, months	OS, months	
1	62/F	8	Acute	0	458	6560	Bone, PB	+	G4	CR	CR	-	-	-	50.5	50.5	Alive in CR
2	80/F	4	Acute	2	339	21,869	PB, skin, LN	+	G4	CR	CR	-	CR	CR	6	6.5	ATL
3	62/F	8	Acute	2	411	37,644	PB, skin, CNS	+	G3	CR	CR	-	CR	CR	18	20	ATL
4	57/M	7	Acute	4	267	2810	Skin, LN	-	G3	CR	CR	-	CR	CR	10.5	13.5	ATL
5	59/M	5	Lymphoma	2	322	6586	PB, skin, LN	+	G2	CR	CR	-	CR	CR	31	31	Alive in CR
6	83/F	4	Acute	1	355	17,137	PB, skin, LN	-	G2	PD	PR	-	PD	CR	0	9	Alive
7	69/F	8	Lymphoma	1	265	1640	LN	+	G1	CR	CR	-	CR	CR	65	65	Alive in CR
8	68/F	4	Acute	3	298	8830	PB, LN	+	-	PR	CR	-	PR	CR	4	24	Pneumonia
9	73/F	8	Acute	2	657	37,998	PB, skin, LN	+	-	PR	CR	-	PR	CR	3.5	18.5	ATL
10	55/M	4	Acute	7	421	2780	Skin	-	-	SD	-	-	SD	-	0	16.5	ATL
11	70/F	8	Chronic	1	209	3415	PB	+	-	CR	CR	-	CR	CR	8	13	ATL
12	71/M	8	Acute	1	431	7382	PB, skin, LN	-	-	SD	CR	-	SD	SD	2	12	Alive
13	69/F	1	Acute	2	501	11,917	PB, skin, lung	-	-	SD	SD	-	SD	SD	0	11	Pneumonia
14	64/M	4	Acute	1	185	2160	LN	+	-	PD	-	-	PD	-	0	9	ATL
15	75/F	8	Acute	1	492	16,526	PB	-	-	CR	CR	-	CR	CR	4	6	Alive
16	79/M	8	Acute	1	187	6377	PB, skin, LN	-	-	SD	CR	-	SD	CR	2	5	Alive
17	79/M	2	Acute	1	2011	48,220	PB	+	-	PR	PR	-	PR	PR	0.5	4.5	ATL
18	62/M	4	Acute	3	292	40,430	PB, skin, LN	+	-	PD	CR	-	PD	CR	0	4	ATL
19	63/M	4	Acute	1	797	6791	PB, skin, LN	-	-	PD	CR	-	PD	CR	0	3	ATL
20	76/M	3	Acute	2	598	8555	PE, PB	+	-	PR	CR	-	PR	CR	1.5	3	ATL
21	55/M	2	Acute	1	1996	5158	PB, CNS	+	-	PD	CR	-	PD	CR	0	2.5	ATL
22	71/M	1	Acute	1	475	1789	PB	+	-	PD	PD	-	PD	PD	0	2	ATL
23	60/M	3	Chronic	1	150	38,335	PB, skin, LN, CNS	-	-	PR	PR	-	PR	PR	0	1	ATL
24	57/M	2	Acute	2	1400	7744	PB, skin, LN, CNS	-	-	PD	PR	-	PD	PR	0	1	ATL
25	64/F	3+	Chronic	1	235	4890	PB, LN, lung	+	-	SD	CR	-	SD	CR	1	1	Alive
26	65/F	4	Acute	1	409	55,400	PB, BM	+	-	PR	PR	-	PR	PR	1	1	Alive

Bold indicates the patients who received 3 or less cycles of mogamulizumab treatment.

PB: peripheral blood; LN: lymph node; PE: pleural effusion; CNS: central nervous system; BM: bone marrow; PR: partial remission; CR: complete remission; SD: stable disease; PD: progressive disease; OS: overall survival; PFS: Progression-free survival.